Bernhard J. Eigl

10.3k total citations · 2 hit papers
135 papers, 4.6k citations indexed

About

Bernhard J. Eigl is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Bernhard J. Eigl has authored 135 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Pulmonary and Respiratory Medicine, 52 papers in Surgery and 46 papers in Oncology. Recurrent topics in Bernhard J. Eigl's work include Prostate Cancer Treatment and Research (48 papers), Bladder and Urothelial Cancer Treatments (33 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Bernhard J. Eigl is often cited by papers focused on Prostate Cancer Treatment and Research (48 papers), Bladder and Urothelial Cancer Treatments (33 papers) and Radiopharmaceutical Chemistry and Applications (25 papers). Bernhard J. Eigl collaborates with scholars based in Canada, United States and United Kingdom. Bernhard J. Eigl's co-authors include Kim N., Christian Kollmannsberger, Scott North, Martin Gleave, Peter Venner, Daniel Y.C. Heng, Arun Azad, Jennifer J. Knox, Joseph D. Ruether and Mark Warren and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

Bernhard J. Eigl

127 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Mark Warren, Bernhard J. Eigl et al. Journal of Clinical Oncology profile →
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Bernhard J. Eigl

Since Specialization

Citations

This map shows the geographic impact of Bernhard J. Eigl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernhard J. Eigl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernhard J. Eigl more than expected).

Fields of papers citing papers by Bernhard J. Eigl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernhard J. Eigl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernhard J. Eigl. The network helps show where Bernhard J. Eigl may publish in the future.

Co-authorship network of co-authors of Bernhard J. Eigl

This figure shows the co-authorship network connecting the top 25 collaborators of Bernhard J. Eigl. A scholar is included among the top collaborators of Bernhard J. Eigl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernhard J. Eigl. Bernhard J. Eigl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer 2025 ·The Oncologist ·Emiliano Calvo, Bernard Doger, Joan Carles, Avivit Peer, David Sarid, Bernhard J. Eigl, Anjali Narayan Avadhani, (unknown), Vincent Lin, Shujian Wu, (unknown), John T. Loffredo, (unknown), Weichun Xu, Hong Xie, Aaron R. Hansen	2
2	Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer 2025 ·JCO Clinical Cancer Informatics ·(unknown), (unknown), (unknown), Ka Mun Nip, (unknown), Arman Rahmim, Robert H. Bell, Corinne Maurice‐Dror, Maryam Soleimani, Kim Chi, Bernhard J. Eigl, Craig R. Nichols, Christian Kollmannsberger, Ren Yuan, Lucia Nappi	1
3	NEO-BLAST: Neoadjuvant therapy for bladder cancer followed by active surveillance vs treatment. 2025 ·Journal of Clinical Oncology ·(unknown), Bernhard J. Eigl, (unknown), Silvia D. Chang, Peter C. Black	1
4	The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast 2024 ·Advances in Therapy ·Peter C. Black, Bernhard J. Eigl	1
5	Abstract A007: Circulating tumor DNA and tissue staining analyses reveal heterogeneous ERBB2/HER2 status in urothelial cancer 2024 ·Clinical Cancer Research ·Gillian Vandekerkhove, Andrew J. Murtha, David C. Müller, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Cecily Q. Bernales, (unknown), Gang Wang, Tilman Todenhöfer, Piet Ost, Peter C. Black, Kim N., Bernhard J. Eigl, Alexander W. Wyatt	0
6	Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma 2023 ·Clinical Cancer Research ·Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sébastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru Sonpavde, Alicia K. Morgans, (unknown), (unknown), (unknown), (unknown), Evan Y. Yu	2
7	Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy. 2023 ·Journal of Clinical Oncology ·Elena Schönlau, David C. Müller, Gillian Vandekerkhove, Andrew J. Murtha, Jack V. W. Bacon, (unknown), (unknown), Sunil Parimi, Krista Noonan, Naveen S. Basappa, Jenny J. Ko, Daygen L. Finch, Nimira Alimohamed, Tarek A. Bismar, Lucia Nappi, Matti Annala, Cecily Q. Bernales, Kim N., Alexander W. Wyatt, Bernhard J. Eigl	0
8	Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition 2021 ·Clinical Cancer Research ·Matti Annala, Sinja Taavitsainen, Daniel Khalaf, Gillian Vandekerkhove, Kevin Beja, Joonatan Sipola, Evan W. Warner, Cameron Herberts, Amanda Wong, Simon Fu, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Bernhard J. Eigl, (unknown), Matti Nykter, Martin Gleave, Kim N., Alexander W. Wyatt	52
9	Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score–weighted comparative cohort study 2021 ·European Journal of Cancer ·Maryam Soleimani, (unknown), Katherine Sunderland, Werner J. Struss, Bernhard J. Eigl, Lucia Nappi, Christian Kollmannsberger, Daygen L. Finch, Krista Noonan, Joanna Vergidis, Muhammad Zulfiqar, Kim N., Daniel Khalaf	11
10	Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer 2021 ·Nature Communications ·Gillian Vandekerkhove, Jean‐Michel Lavoie, Matti Annala, Andrew J. Murtha, Nora Sundahl, Simon Walz, Takeshi Sano, Sinja Taavitsainen, Elie Ritch, Ladan Fazli, Antonio Hurtado‐Coll, Gang Wang, Matti Nykter, Peter C. Black, Tilman Todenhöfer, Piet Ost, Ewan A. Gibb, Kim N., Bernhard J. Eigl, Alexander W. Wyatt	109
11	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada 2020 ·Bladder Cancer ·Di Jiang, Scott North, Christina Canil, Michael Kolinsky, Lori Wood, Samantha Gray, Bernhard J. Eigl, Naveen S. Basappa, Normand Blais, Eric Winquist, Som D. Mukherjee, Christopher M. Booth, Nimira Alimohamed, Piotr Czaykowski, Girish S. Kulkarni, Peter C. Black, Peter Chung, Wassim Kassouf, Theodorus van der Kwast, Srikala S. Sridhar	2
12	Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma 2019 ·Canadian Urological Association Journal ·Mark Warren, Michael Kolinsky, Christina M. Canil, Piotr Czaykowski, Srikala S. Sridhar, Peter C. Black, Christopher M. Booth, Wassim Kassouf, Libni Eapen, Som D. Mukherjee, Normand Blais, Bernhard J. Eigl, Eric Winquist, Naveen S. Basappa, Scott North	9
13	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer breakdown → 2018 ·Cancer Discovery ·Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Evan W. Warner, Katherine Sunderland, Christian Kollmannsberger, Bernhard J. Eigl, Daygen L. Finch, Conrad D. Oja, Joanna Vergidis, Muhammad Zulfiqar, Arun Azad, Matti Nykter, Martin Gleave, Alexander W. Wyatt, Kim N.	347
14	An augmented reality navigation system for laparoscopic liver surgery – First experiences 2018 ·HPB ·Iwan Paolucci, Bernhard J. Eigl, (unknown), Anja Lachenmayer, Matthias Peterhans, Stefan Weber, Daniel Candinas, Guido Beldi	2
15	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer 2017 ·Clinical Cancer Research ·Gillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, Werner J. Struss, Amanda Wong, Kevin Beja, Elie Ritch, Sonal Brahmbhatt, Stanislav Volik, Jörg Hennenlotter, Matti Nykter, Kim N., Scott North, Arnulf Stenzl, Colin C. Collins, Bernhard J. Eigl, Peter C. Black, Alexander W. Wyatt	122
16	Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer 2017 ·Annals of Oncology ·Joaquim Bellmunt, Bernhard J. Eigl, Elżbieta Senkus, Yohann Loriot, P. Twardowski, Daniel Castellano, Normand Blais, Srikala S. Sridhar, Cora N. Sternberg, Margitta Retz, Sumanta K. Pal, Brent A. Blumenstein, Cindy Jacobs, Patricia Stewart, Daniel P. Petrylak	19
17	Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis 2016 ·Annals of Oncology ·Andrea Necchi, Gregory R. Pond, Daniele Raggi, Sarah R. Ottenhof, Simon Horenblas, Vincent Khoo, (unknown), Axel Heidenreich, Bernhard J. Eigl, Lucia Nappi, Kazuya Matsumoto, Ulka N. Vaishampayan, (unknown), Patrizia Giannatempo, Daniel M. Geynisman, Mirko Preto, (unknown), Matthew I. Milowsky, Giuseppe Di Lorenzo, Guru Sonpavde	0
18	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel 2015 ·Annals of Oncology ·(unknown), Thian Kheoh, Charles J. Ryan, A. Molina, Joaquim Bellmunt, Nicholas J. Vogelzang, Dana E. Rathkopf, Karim Fizazi, Philip W. Kantoff, (unknown), Arun Azad, Bernhard J. Eigl, D.Y.C. Heng, Anthony M. Joshua, Johann S. de Bono, Howard I. Scher	132
19	A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a 2011 ·Annals of Oncology ·(unknown), (unknown), Bernhard J. Eigl, Peter Venner, Sébastien J. Hotte, (unknown), Yoo-Joung Ko, Srikala S. Sridhar, Dirk Weber, Fred Saad	29
20	A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) 2007 ·Journal of Clinical Oncology ·(unknown), Sébastien J. Hotte, Evan Y. Yu, Bernhard J. Eigl, I. Tannock, Fred Saad, Scott North, Joseph D. Powers, E. Eisenhauer	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact